

George Grunberger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8344875/publications.pdf>

Version: 2024-02-01

87
papers

10,368
citations

50244

46
h-index

58549

82
g-index

87
all docs

87
docs citations

87
times ranked

9166
citing authors

#	ARTICLE	IF	CITATIONS
1	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
2	American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. <i>Endocrine Practice</i> , 2021, 27, 505-537.	1.1	135
3	Reply to N. Viridi. <i>Endocrine Practice</i> , 2021, 27, 1063.	1.1	0
4	Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. <i>Diabetes Care</i> , 2020, 43, 37-43.	4.3	168
5	Human regular Uâ€500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 434-441.	2.2	28
6	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm â€“ 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224.	1.1	117
7	Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 2744-2750.	4.3	83
8	Continuous glucose monitoring: Musing on our progress in memory of Dr Andrew Jay Drexler. <i>Journal of Diabetes</i> , 2020, 12, 772-774.	0.8	0
9	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019, 42, 1593-1603.	4.3	2,101
10	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodiumâ€“Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , 2019, 42, 1147-1154.	4.3	249
11	Fred W. Whitehouse, MD, MACP (1926â€“2019). <i>Diabetes Care</i> , 2019, 42, 2167-2170.	4.3	0
12	Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study. <i>Diabetes Therapy</i> , 2018, 9, 49-66.	1.2	99
13	American Association of Clinical Endocrinologists And American College of Endocrinology 2018 Position Statement On Integration of Insulin Pumps And Continuous Glucose Monitoring In Patients With Diabetes Mellitus. <i>Endocrine Practice</i> , 2018, 24, 302-308.	1.1	37
14	Dysglycemia-Based Chronic Disease: An American Association of Clinical Endocrinologists Position Statement. <i>Endocrine Practice</i> , 2018, 24, 995-1011.	1.1	63
15	Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2018, 41, 2275-2280.	4.3	396
16	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. <i>Current Diabetes Reports</i> , 2017, 17, 21.	1.7	33
17	Letter to the Editor. <i>Endocrine Practice</i> , 2017, 23, 629-632.	1.1	12
18	American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. <i>Endocrine Practice</i> , 2016, 22, 231-262.	1.1	97

#	ARTICLE	IF	CITATIONS
19	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. <i>Endocrine Practice</i> , 2016, 22, 753-762.	1.1	242
20	Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm “ 2016 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016, 22, 84-113.	1.1	405
21	Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. <i>Endocrine Practice</i> , 2016, 22, 1008-1021.	1.1	151
22	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 776-790.	1.7	105
23	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 2026-2035.	4.3	197
24	American Association of Clinical Endocrinologists and American College of Endocrinology “ Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan “ 2015 “ Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 413-437.	1.1	359
25	AACE/ACE Comprehensive Diabetes Management Algorithm 2015. <i>Endocrine Practice</i> , 2015, 21, 438-447.	1.1	189
26	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY–CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN–2015–EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2015, 21, 413-37.	1.1	36
27	American Association of Clinical Endocrinologists and American College of Endocrinology Consensus Conference on Obesity: Building an Evidence Base for Comprehensive Action. <i>Endocrine Practice</i> , 2014, 20, 956-976.	1.1	33
28	Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1277-1289.	0.8	6
29	Obesity Management: Applying Clinical Trial Data to Clinical Care. <i>Endocrine Practice</i> , 2014, 20, 6-19.	1.1	2
30	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. <i>Endocrine Practice</i> , 2014, 20, 977-989.	1.1	172
31	Response to Comment on Grunberger “Insulin Analogs” Are They Worth It? Yes! “ <i>Diabetes Care</i> 2014;37:1767-1770 and Davidson “Insulin Analogs” Is There a Compelling Case to Use Them? No! “ <i>Diabetes Care</i> 2014;37:1771-1774. <i>Diabetes Care</i> , 2014, 37, e232-e232.		0
32	The Traditions and Risks of Fasting for Lipid Profiles in Patients with Diabetes. <i>Postgraduate Medicine</i> , 2014, 126, 98-107.	0.9	14
33	Cardiovascular safety trials: Be careful what you wish for (<i>Journal of Diabetes</i>).		
34	Insulin Analogs “ Are They Worth It? Yes!. <i>Diabetes Care</i> , 2014, 37, 1767-1770.	4.3	65
35	Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology Insulin Pump Management Task Force. <i>Endocrine Practice</i> , 2014, 20, 463-489.	1.1	140
36	Novel therapies for the management of type 2 diabetes mellitus: Part 1. Pramlintide and bromocriptine “ QR “ (<i>Journal of Diabetes</i>).	0.8	29

#	ARTICLE	IF	CITATIONS
37	American Association of Clinical Endocrinologists™ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 1-48.	1.1	132
38	Will PPAR- γ agonist therapy still have a role in diabetes management in 2013?. <i>Diabetes Management</i> , 2013, 3, 41-51.	0.5	1
39	Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (æ-°âž<2âž<ç³-â°;ç—...æ²>ç—è•ç%©i1/4šç-12éf"â†. 2013â1'â,â°Sâ,Šé'^-1è,âj,fèfâ²>ç'ç1/4šè™.çš,,æ		
40	Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin. <i>Postgraduate Medicine</i> , 2013, 125, 79-90.	0.9	8
41	Enhancing insulin-use safety in hospitals: Practical recommendations from an ASHP Foundation expert consensus panel. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1404-1413.	0.5	95
42	Diabetes and Cancer—An AACE/ACE Consensus Statement. <i>Endocrine Practice</i> , 2013, 19, 675-693.	1.1	78
43	Aace Comprehensive Diabetes Management Algorithm 2013. <i>Endocrine Practice</i> , 2013, 19, 327-336.	1.1	318
44	Quo vadisnateglinide? Ten-year perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2097-2106.	0.9	1
45	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan: Executive Summary. <i>Endocrine Practice</i> , 2011, 17, 287-302.	1.1	80
46	Do we need a fasting lipid profile to assess cardiovascular risk?. <i>Journal of Diabetes</i> , 2011, 3, 172-173.	0.8	5
47	Statement by the American Association of Clinical Endocrinologists Consensus Panel on Insulin Pump Management. <i>Endocrine Practice</i> , 2010, 16, 746-762.	1.1	53
48	Statement by the American Association of Clinical Endocrinologists Consensus Panel on Continuous Glucose Monitoring. <i>Endocrine Practice</i> , 2010, 16, 730-745.	1.1	78
49	Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. <i>Endocrine Practice</i> , 2009, 15, 540-559.	1.1	805
50	Diagnosis and Management of Prediabetes in the Continuum of Hyperglycemia—When Do the Risks of Diabetes Begin? A Consensus Statement From the American College of Endocrinology and the American Association of Clinical Endocrinologists*. <i>Endocrine Practice</i> , 2008, 14, 933-946.	1.1	187
51	Abnormalities of Vitamin D and Calcium Metabolism after Surgical Treatment of Morbid Obesity: A Study of 136 Patients. <i>Endocrine Practice</i> , 2007, 13, 131-136.	1.1	23
52	Road Maps to Achieve Glycemic Control in Type 2 Diabetes Mellitus. <i>Endocrine Practice</i> , 2007, 13, 260-268.	1.1	71
53	The benefits of early intervention in obese diabetic patients with FBCxâ,,ç â€” a new dietary fibre. <i>Diabetes/Metabolism Research and Reviews</i> , 2007, 23, 56-62.	1.7	69
54	Fetuin-null mice are protected against obesity and insulin resistance associated with aging. <i>Biochemical and Biophysical Research Communications</i> , 2006, 350, 437-443.	1.0	109

#	ARTICLE	IF	CITATIONS
55	Effect of a Peroxisome Proliferator-Activated Receptor- α Agonist on Myocardial Blood Flow in Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 1145-1150.	4.3	26
56	The C-peptide Signaling. <i>Experimental Diabetes Research</i> , 2004, 5, 25-36.	1.0	26
57	Type 1 Diabetic Neuropathy and C-peptide. <i>Experimental Diabetes Research</i> , 2004, 5, 65-77.	1.0	42
58	Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1387-1393.	1.2	426
59	Addition of Nateglinide to Rosiglitazone Monotherapy Suppresses Mealtime Hyperglycemia and Improves Overall Glycemic Control. <i>Diabetes Care</i> , 2003, 26, 1685-1690.	4.3	37
60	Improved Insulin Sensitivity and Resistance to Weight Gain in Mice Null for the Ahsg Gene. <i>Diabetes</i> , 2002, 51, 2450-2458.	0.3	320
61	Plasma α 2-HS glycoprotein concentrations in patients with acute myocardial infarction quantified by a modified ELISA. <i>Clinica Chimica Acta</i> , 2002, 319, 27-34.	0.5	22
62	Hippocampal neuronal apoptosis in type 1 diabetes. <i>Brain Research</i> , 2002, 946, 221-231.	1.1	282
63	Coronary vascular dysfunction in premenopausal women with diabetes mellitus. <i>American Heart Journal</i> , 2002, 144, 711-8.	1.2	13
64	C-Peptide Attenuates Protein Tyrosine Phosphatase Activity and Enhances Glycogen Synthesis in L6 Myoblasts. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 615-619.	1.0	52
65	Genetic Mapping and Functional Studies of a Natural Inhibitor of the Insulin Receptor Tyrosine Kinase: The Mouse Ortholog of Human α 2-HS Glycoprotein. <i>International Journal of Experimental Diabetes Research</i> , 2000, 1, 249-263.	1.0	15
66	Effects of Autonomic Neuropathy on Coronary Blood Flow in Patients With Diabetes Mellitus. <i>Circulation</i> , 1999, 100, 813-819.	1.6	230
67	The Reliability of the Diabetes Care Profile for African Americans. <i>Evaluation and the Health Professions</i> , 1998, 21, 52-65.	0.9	54
68	α 2-Heremans Schmid Glycoprotein Inhibits Insulin-Stimulated Elk-1 Phosphorylation, But Not Glucose Transport, in Rat Adipose Cells. <i>Endocrinology</i> , 1998, 139, 4147-4154.	1.4	3
69	Differences in the Impact of Dietary Restrictions on African Americans and Caucasians With NIDDM. <i>The Diabetes Educator</i> , 1997, 23, 41-47.	2.6	32
70	Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. <i>Life Sciences</i> , 1997, 61, 1583-1592.	2.0	56
71	Recombinant human α 2-HS glycoprotein inhibits insulin-stimulated mitogenic pathway without affecting metabolic signalling in Chinese hamster Ovary cells overexpressing the human insulin receptor. <i>Cellular Signalling</i> , 1996, 8, 567-573.	1.7	22
72	Diabetes and Related Metabolic Risk Factors Among Arab Americans. <i>Annals of Pharmacotherapy</i> , 1995, 29, 573-576.	0.9	25

#	ARTICLE	IF	CITATIONS
73	Continuous versus Intermittent Sulphonylurea Therapy in Non-Insulin-Dependent Diabetes Mellitus. <i>Drug Safety</i> , 1993, 9, 249-253.	1.4	8
74	Functional characterization of insulin and IGF-I receptors in chicken lens epithelial and fiber cells. <i>Current Eye Research</i> , 1992, 11, 1137-1145.	0.7	36
75	Diacylglycerols modulate phosphorylation of the insulin receptor from human mononuclear cells. <i>FEBS Journal</i> , 1990, 187, 191-198.	0.2	11
76	High-fat feeding induces tissue-specific alteration in proportion of activated insulin receptors in rats. <i>European Journal of Endocrinology</i> , 1990, 122, 361-368.	1.9	34
77	Effects of food restriction and insulin treatment on (Ca ²⁺ + Mg ²⁺)-ATPase response to insulin in kidney basolateral membranes of noninsulin-dependent diabetic rats. <i>Metabolism: Clinical and Experimental</i> , 1990, 39, 25-33.	1.5	22
78	Factitious Hypoglycemia Due to Surreptitious Administration of Insulin. <i>Annals of Internal Medicine</i> , 1988, 108, 252.	2.0	90
79	Use of tyrosine-containing polymers to characterize the substrate specificity of insulin and other hormone-stimulated tyrosine kinases. <i>FEBS Journal</i> , 1985, 148, 177-182.	0.2	87
80	Tyrosine Kinase Activity of the Insulin Receptor of Patients with Type A Extreme Insulin Resistance: Studies with Circulating Mononuclear Cells and Cultured Lymphocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 59, 1152-1158.	1.8	73
81	Insulin-like growth factor-I (IGF-I) stimulates tyrosine kinase activity in purified receptors from a rat liver cell line. <i>Biochemical and Biophysical Research Communications</i> , 1984, 119, 6-13.	1.0	92
82	The insulin-stimulated receptor kinase is a tyrosine-specific casein kinase. <i>FEBS Journal</i> , 1983, 137, 631-637.	0.2	29
83	11 Insulin receptors in normal and disease states. <i>Clinics in Endocrinology and Metabolism</i> , 1983, 12, 191-219.	1.8	44
84	Protein kinase activity of the insulin receptor in human circulating and cultured mononuclear cells. <i>Biochemical and Biophysical Research Communications</i> , 1983, 115, 560-566.	1.0	52
85	Insulin stimulates phosphorylation of serine residues in soluble insulin receptors. <i>Biochemical and Biophysical Research Communications</i> , 1983, 116, 1129-1135.	1.0	54
86	Hypoglycemia Associated with Antibodies to the Insulin Receptor. <i>New England Journal of Medicine</i> , 1982, 307, 1422-1426.	13.9	144
87	Stimulating Results Signal a New Treatment Option for People Living With Painful Diabetic Neuropathy. <i>Journal of Diabetes Science and Technology</i> , 0, , 193229682210995.	1.3	0